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Background/aim: This study aimed to identify IDUA gene mutations in Turkish patients morphologically (phenotypic) diagnosed
with MPS type I. It also sought to discuss the possible effects of detected mutations on alpha-L-iduronidase enzyme function based on
current knowledge.
Materials and methods: Genetic analysis was carried out in 15 patients using direct DNA sequencing. Moreover, segregation analysis
was performed among family members to predict the pathogenic effect of novel mutations, and computational programs were used to
predict their functional impact.
Results: Nine different mutations (c.494-1G>A, c.793-6C>G, c.793-5C>A, p.M1L, p.Y64X, p.A327P, p.W402X, p.P533L, and p.R628X)
were identified. Computational analysis results supported the pathogenicity of novel mutations, suggesting improper splicing. Seven
already-known polymorphisms were detected in the screened cohort as well.
Conclusion: Our results revealed heterogeneity in the mutation spectrum of Turkish patients. Six of the mutations, including the novel
ones, have never before been reported in the Turkish population. Moreover, 5 patients who were phenotypically diagnosed with MPS
type I could not be confirmed by genetic analysis, indicating the importance of the molecular characterization of MPS subtypes.
Key words: IDUA gene, mutation analysis, MPS type I, alpha-L-iduronidase

1. Introduction
Mucopolysaccharidosis type I (MPS type I) is a rare
autosomal recessive disorder resulting from deficiency
of α-L-iduronidase (IDUA, EC 3.2.1.76), an important
lysosomal enzyme in the catabolism of dermatan sulfate
and heparan sulfate. Patients with MPS type I are unable
to degrade dermatan and heparan sulfates, resulting in
the progressive storage of glycosaminoglycans within the
lysosomes.
MPS type I is classified according to the enzymatic
activity of IDUA, while affected individuals are further
classified into three main groups: Hurler syndrome (MPS
I-H; OMIM# 607014), Hurler–Scheie syndrome (MPS
I-HS; OMIM# 607015), and Scheie syndrome (MPS I-S;
OMIM# 607016) (1). MPS type I occurs in approximately
1/100,000 people worldwide. MPS I-H is the most
common, while MPS I-S is a rare form (2,3).
MPS type I is a progressive multisystemic disorder
with a wide range of clinical manifestations. These include
* Correspondence: mkaraca@aksaray.edu.tr
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coarse facial features, hepatosplenomegaly, dysostosis
multiplex, severe arthropathy, visual impairment, hearing
loss, restrictive lung disease, upper airway obstruction,
valvular heart disease, communicating hydrocephalus,
mental retardation, and spinal cord compression. The
phenotype is usually characterized as Hurler syndrome
when the onset of the symptoms occurs before 12 months
of age. Survival is then estimated to be around 10 years
and mental retardation manifests before the age of 3 years.
For Hurler–Scheie syndrome, the onset of the disease is
between 1 and 6 years, survival is variable, and mental
retardation is absent or mild, but is not present before 3
years of age. Scheie syndrome manifests itself after 5 years
of age, survival is normal, and mental retardation is absent
(4).
MPS type I is diagnosed by measuring IDUA enzyme
activity in urine, leukocytes, and cultured skin fibroblasts.
Hematopoietic stem cell transplantation (HSCT) and
enzyme replacement therapy (ERT) can effectively treat
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MPS I subtypes. ERT may be used to treat Hurler–Scheie
and Scheie syndromes, while the application of both ERT
and HSCT is pivotal to successful treatment of Hurler
syndrome (5–7). The IDUA gene is approximately 19 kb
in length. It maps to chromosome 4p16.3 and contains 14
exons, producing a transcript of 2.3 kb in length, which
encodes a precursor protein consisting of 653 amino
acids (8). The first 27 amino acids of the protein represent
a signal peptide. To date, 199 different disease-causing
IDUA gene mutations have been reported (9) (http://www.
hgmd.org), with variable distribution across populations.
Among them, p.W402X, p.Q70X, p.P533R, and p.G51D
are the most common mutations worldwide. p.W402X
has a frequency of approximately 50% in northern Europe,
the United Kingdom, North America (10–12), and
Spain (13). However, it appears less frequently in Russia
(4%) (14), Italy (11%) (4,15), and Brazil (20%) (16). The
frequency of p.Q70X is 50% in Russia and Scandinavia; it
appears less often in other countries (14,17). p.G51D is a
common mutation in Italy, with a frequency of 13% (4).
It was reported that p.P533R originated in North Africa
and is common in Mediterranean countries, appearing at
a frequency of 13% in Italy and 10% in Spain (4,14,18).
These findings clearly demonstrate that the distribution
of IDUA gene mutations is varied among populations.
The main purpose of the present study was to identify
IDUA gene mutations in Turkish patients morphologically
(phenotypic) diagnosed with MPS type I and to discuss the
possible effects of detected mutations on IDUA enzyme
function.
2. Materials and methods
The study’s participants were patients from Hacettepe
University, from within the Faculty of Medicine,
Metabolism Unit of the Department of Pediatrics.
Approval was obtained from an ethical review board and
the principles outlined in the Declaration of Helsinki
regarding human experimental investigations were
followed. In total, 15 patients were screened for mutations
in the IDUA gene.
Genomic DNA was isolated from peripheral blood
samples (10 mL) using a standard salting-out method.
All IDUA exons were amplified using intronic primers
flanking the exonic nucleotide sequences. Standard and
touchdown PCR analyses were performed in a total volume
of 25 μL (1X PCR buffer, 1.5 mM MgCl2, 200 μM of each
dNTPs, 50 pmol of each primer, and 0.5 U HotStartTaq
DNA polymerase), using 50 ng of genomic DNA. PCR
products were purified with MinElute 96 UF plate systems
(Qiagen, Hilden, Germany). Samples were sequenced in
both directions using the BigDye Terminator Kit version
3.1 (Applied Biosystems, Foster City, CA, USA) and were
analyzed in an automated DNA sequencer (ABI 3130,

Applied Biosystems). Analysis Software version 5.2 Patch
2 (Applied Biosystems) was used for data evaluation.
One hundred healthy chromosomes were screened
for novel substitutions via DNA sequencing, while
computational programs (ASSEDA and NetGene2) were
used to predict the putative effect of novel mutations.
3. Results
In this study, 15 Turkish patients with MPS type I were
screened for IDUA gene mutations using direct DNA
sequencing. Ten of the screened patients were carriers of
nine different mutations. These included two novel (c.7936C>G, c.793-5C>A) splice site substitutions, 7 alreadyreported missense (p.M1L, p.A327P, p.P533L), nonsense
(p.Y64X, p.W402X, p.R628X), and splice site (c.4941G>A) mutations (Table).
Using the aforementioned programs, we were able to
predict the impact of novel mutations on protein function.
The results indicate that both mutations affect a splice
mechanism between intron 6 and exon 7. Neither novel
mutation was observed in the 100 healthy chromosomes.
Nine of the screened patients were carriers of
homozygous IDUA gene mutations. Compound
heterozygosity was observed in the other patients.
The c.494-1G>A splice mutation seems common and
was detected in three out of the 10 patients. Additionally,
rare p.Y64X and p.P533L mutations could be detected in
the screened cohort.
DNA sequencing analysis revealed 7 different
previously described polymorphisms (p.A8A, p.A20A,
p.H33Q, p.R105Q, p.A314A, p.T410T and IVS5-8C > T).
We were unable to find IDUA gene mutations in the 5
patients diagnosed with MPS-I.
4. Discussion
Screening genetic variations that exhibit variable allelic
distribution across populations facilitates the assessment
of the genetic profile of populations and the development
of appropriate medical strategies to prevent severe
symptoms. Due to the limited sample size in studies of
genetic disorders, the results obtained from many different
studies provide knowledge regarding the disease-associated
mutation spectrum for a given population. In this study,
15 Turkish patients were screened and 9 different IDUA
gene mutations were determined. The mutation spectrum
in the screened cohort was heterogeneous. We could
identify novel c.793-5C>A and c.793-6C>G substitutions,
in addition to p.M1L, p.Y64X, p.P533L, and p.R628X,
which have not previously been reported in the Turkish
population. Furthermore, p.A327P and the common
p.W402X mutation was described in the screened cohort,
along with the c.494-1G>A mutation, which was already
indicated as specific to the Turkish population.
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Table. Mutation patterns for the IDUA gene in Turkish patients with MPS type I.
Patient ID

Nucleotide position

Protein

Subtype

1

c.1A>C

p.M1L(hom)

Hurler

2

c.192C>A/
c.1067G>C

p.Y64X/p.A327P

Hurler

3

*c.494-1G>A

p.R166GfsX27(hom)

Hurler

4

*c.494-1G>A

p.R166GfsX27(hom)

Hurler

5

*c.494-1G>A

p.R166GfsX27(hom)

Hurler

6

*c.793-5C>A(hom)/
*c.793-6C>G(hom)

Splice site

Hurler/Scheie

p.W402X(hom)

Hurler

7

c.1205G>A

8

c.1205G>A

p.W402X(hom)

Hurler

9

c.1598C>T

p.P533L(hom)

Hurler/Scheie

10

c.1882C>T

p.R628X (hom)

Hurler

The numbering of nucleotide changes is based on cDNA sequence in accordance with the GenBank entries
NM_ 000203.3. The amino acid numbers were designed according to the ENST 00000247933.
hom: homozygous.
*Intronic mutations.

Both of the novel mutations were detected in a
homozygous state in one of the screened patients
manifesting the Hurler–Scheie phenotype. Segregation
analysis revealed that healthy family members were
carriers of the same variation in a heterozygous fashion.
Computational analysis, which was used to predict
pathogenicity of these variations, indicated improper
splicing between intron 6 and exon 7.
One of the screened patients had a homozygous p.M1L
mutation, which causes a skipping of 133 amino acids
and leads to a synthesis of an inactive, truncated enzyme
(19). Consequently, the next methionine serves as the start
codon and the produced enzyme loses the amino acids
encoded by exons 1, 2, and 3. In addition, p.M1L leads to
a loss of the signal peptide sequence of the protein, which
results in the disruption of the transport process into the
endoplasmic reticulum and lysosomes (19). This mutation
has already been reported in Chinese and Spanish (19,20)
patients.
The p.Y64X mutation is known as a rare alteration that
generates a premature stop codon, which truncates the
protein by 589 amino acids. It has already been reported in
the Israeli Arab community (21). We found this mutation
to be a compound heterozygous state with p.A327P.
Variable frequency was observed for the p.A327P across
different populations. It was reported at a frequency of 11%
for Central Europe (German and Dutch) (11), 3.5%–6%
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for England (11,12), 5.6% for Italy (15), 2.2% for Austria
(22), and 3.3%–8.3% for Brazil (16,23). It is worth noting
that the studies were performed mostly on European
Caucasians and that the frequency of this mutation was
3.5% for Turkish MPS-I patients (24). Proline is an amino
acid that causes loss of flexibility with its angular bond in
the site of localization. Therefore, it may disrupt regular
secondary structures (25). A327 is localized in the interior
face of the 6th α-helices of the protein. Proline at this site
likely affects conformation of the protein and may decrease
its stability as well (25).
Two of the screened patients had the homozygous
p.W402X mutation, which was identified as a common
variation with 45.3% allele frequency in Turkish MPS-I
patients (24). The produced enzyme is inactive and lacks
402 amino acids. Studies reported an association between
the homozygous version of this mutation and severe
Hurler syndrome (12,14). Another mutation associated
with a severe phenotype in a homozygous fashion is
p.R628X, which was observed in one of the patients.
This mutation is localized in exon 14, quite near to the C
terminal part of the IDUA protein. A nonsense mutation
at this site truncates the C terminus and causes a severe
MPS-I phenotype (12,23,26,27).
We observed homozygous c.494-1G>A splice site
mutations in 3 patients. Interestingly, this mutation was
reported as being specific to Turkey (allele frequency,
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41%) (20). The mutation occurs in the last nucleotide of
intron 4. It causes a frameshift starting from position 166.
Following the 27 amino acids, a stop codon is generated.
Truncation of the protein by 193 amino acids leads to
synthesis of an inactive IDUA enzyme, causing severe
expression of the Hurler phenotype (20).
p.P533L is a rare mutation reported only in Russian
patients as a compound heterozygous state (14).We
detected the same mutation in one of the screened patients
in a homozygous fashion. This mutation occurred in
the CpG-rich site of the gene and corresponds to the
functional importance of the C terminal part of the
protein (14). It was reported that mutations occurring in
this site, including p.P533R, are associated with severe
disease phenotypes (12,23,28–30). The results of protein
alignment indicate a similarity between the C terminal
part of the IDUA enzyme and the fibronectin III protein,
which is important in protein–protein interaction (25,26).
The replacement of P533 (such as leucine or arginine
residues) causes a steric conflict to form severe or severeintermediate phenotypes (31).
In addition to the pathogenic mutations, we described
7 known polymorphic variants (p.A8A, p.A20A, p.H33Q,
p.R105Q, IVS5-8C>T, p.A314A, p.T410T) in this cohort.
Up until now, 37 different nonpathogenic variations have

been described (20). No clear information is available
regarding their effect on enzyme activity or stability in
MPS-I patients. However, it is known that polymorphic
variants may contribute to variable IDUA activity in
healthy individuals (32) and may be a cause of the
phenotypic variability of the disease, in combination with
different pathogenic mutations.
Consequently, including novels, we described six
mutations that have not been previously reported in the
Turkish population. The results of the study indicate the
heterogeneous mutation spectrum in this population.
Molecular characterization of the IDUA gene facilitates
a reliable diagnosis of clinical subtypes, which improves
prognostic prediction, provides accurate carrier detection,
and contributes to the development of better therapeutic
approaches.
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